ロード中...
Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
CD20 has proven to be an excellent target for the treatment of B-cell lymphoma, first for the chimeric monoclonal antibody rituximab (Rituxan™), and more recently for the radiolabelled antibodies Y-90 ibritumomab tiuxetan (Zevalin™) and I-131 tositumomab (Bexxar™). Radiation therapy effects are due...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer-Verlag
2006
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2779347/ https://ncbi.nlm.nih.gov/pubmed/16550338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10238-006-0087-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|